Nabriva Therapeutics plc (NBRVF)

Market Cap	646.00
Revenue (ttm)	29.56M
Net Income (ttm)	-55.05M
Shares Out	3.23M
EPS (ttm)	-17.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	127
Average Volume	882
Open	0.0002
Previous Close	n/a
Day's Range	0.0002 - 0.0002
52-Week Range	0.0000 - 0.8850
Beta	-6.99
RSI	37.40
Earnings Date	Mar 28, 2025

About Nabriva Therapeutics

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company’s product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infect...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 39
• Stock Exchange: OTCMKTS
• Ticker Symbol: NBRVF

Financial Performance

In 2022, Nabriva Therapeutics's revenue was $36.94 million, an increase of 27.82% compared to the previous year's $28.90 million. Losses were -$57.19 million, 15.6% more than in 2021.